Kenya has taken a major step forward in its fight against HIV with the arrival of the first shipment of Lenacapavir, a ground breaking long-acting injectable for HIV prevention. The U.S. Embassy in Nairobi announced the milestone, stating that the consignment landed last night, bringing “hope” to the country.
Manufactured by American company Gilead Sciences, Lenacapavir is administered as just two injections per year and offers highly effective pre-exposure prophylaxis (PrEP). It has strong potential to reduce new HIV infections, especially among vulnerable groups such as pregnant and breastfeeding women.
The U.S. government, in partnership with the Global Fund, is co-funding the procurement and distribution of Lenacapavir. This supports access for up to 2 million people globally as part of efforts to achieve an AIDS-free generation.
In Kenya, the initial batch includes 21,000 starter doses, with rollout planned for early March 2026 in 15 high-burden counties. Additional doses are expected soon to sustain the program.
This innovation addresses challenges with daily oral PrEP, such as adherence issues, and could significantly lower infection rates in a country where HIV remains a public health priority. The arrival underscores international collaboration in delivering life-saving health advancements to resource-limited settings.
Author: Bashirjuma
About The Author
